Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Cold Spring Harbor Laboratory, New York, NY, USA; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK.
Eur Urol Focus. 2021 Jul;7(4):717-721. doi: 10.1016/j.euf.2021.04.024. Epub 2021 May 11.
T-cell immunotherapy and molecular targeted therapies have become standard-of-care treatments for renal cell carcinoma (RCC). There is a need to develop robust biomarkers that predict patient outcomes to targeted therapies to personalise treatment. In recent years, quantitative analysis of imaging features, termed radiomics, has been used to extract tumour features. This narrative mini review summarises the evidence for radiomics prediction of immunotherapy and molecular targeted therapy outcomes in RCC. Radiomics may predict survival, treatment response, and disease progression in RCC treated with tyrosine kinase inhibitors (eg, sunitinib) and immune checkpoint inhibitors (eg, nivolumab). Further validation is necessary in large-scale studies. PATIENT SUMMARY: We summarise evidence on the ability of features extracted from CT (computed tomography) scans to predict patient outcomes from new treatments for kidney cancer. Although these features can predict treatment outcomes for patients, including survival, treatment response, and cancer progression, further research is necessary before this technology can be applied clinically.
T 细胞免疫疗法和分子靶向疗法已成为肾细胞癌 (RCC) 的标准治疗方法。需要开发强大的生物标志物来预测靶向治疗的患者预后，以实现个体化治疗。近年来，定量分析成像特征的技术，称为放射组学，已被用于提取肿瘤特征。本叙述性迷你综述总结了放射组学预测 RCC 免疫治疗和分子靶向治疗结果的证据。放射组学可预测接受酪氨酸激酶抑制剂（如舒尼替尼）和免疫检查点抑制剂（如纳武单抗）治疗的 RCC 的生存、治疗反应和疾病进展。需要在大规模研究中进一步验证。患者总结：我们总结了从 CT（计算机断层扫描）扫描中提取的特征预测肾癌新疗法患者预后的能力的证据。虽然这些特征可以预测包括生存、治疗反应和癌症进展在内的患者的治疗结果，但在这项技术可以应用于临床之前，还需要进一步的研究。
